US doctors sanction transplant criteria for liver cancer patients
March 4, 2010 by admin · Leave a Comment
Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell Read more
Cases of liver cancer reduced in a younger population vaccinated for HBV
September 16, 2009 by admin · Leave a Comment
A 20-year follow-up study revealed a dramatic drop in liver cancer cases among 6- to 19-year-olds who were vaccinated for the hepatitis B virus at birth, according to a study published online September 16 in the Journal of the National Cancer Institute.
SAMe is Effective in Preventing Formation of Primary Liver Cancer in Rats
July 30, 2009 by admin · Leave a Comment
A new study investigated the effectiveness of S-adenosylmethionine (SAMe) in the prevention and treatment of hepatocellular carcinoma (HCC) or primary liver cancer. SAMe, a widely available nutritional supplement, with little known side effects, was found to be effective in preventing the formation of HCC in rats. However, high enough levels of SAMe were not attainable to successfully treat established HCC. The findings are available in the August issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases.
A potential drug for liver carcinoma identified
May 24, 2009 by admin · Leave a Comment
Looking for efficient anti-tumor drugs is a hot research area. Chrysin (5,7-dihydroxy flavone), a natural widely-distributed flavonoid, has been reported to have many different biological activities such as anti-oxidant, anti-virus, antidiabetogenic activity and clear anxiolytic effect. However, Chrysin is limited in its clinical application because of its modest absorption in the intestine and rapid in vivo glycosylation. To improve the biological activity of chrysin, a number of its derivatives have been prepared for biological testing. 5-allyl-7-gen-difluoromethylenechrysin (ADFMChR) is one of them.
Long-term L-carnitine supplementation prevents development of liver cancer
March 24, 2009 by admin · Leave a Comment
A study will be published on March 21, 2009 in World Journal of Gastroenterology addresses the question. A research group in King Saud University, Kingdom of Saudi Arabia investigated, for the first time, the role of carnitine, a naturally occurring compound that is synthesized mainly in the liver, during the development of hepatocarcinogenesis. Authors of the study reported that carnitine deficiency is a risk factor and should be viewed as a mechanism in hepatic carcinogenesis, and that long-term L-carnitine supplementation prevents the development of liver cancer. Therefore, carnitine supplementation alone or in combination with other natural chemopreventive compounds could be used to prevent, slow or reverse the occurrence of liver cancer.
Oncostatin M may be a promising drug for treating viral hepatitis and liver cancer
February 9, 2009 by admin · Leave a Comment
The Department of Gene Therapy and Hepatology of the Center for Applied Medical Research (CIMA) of the University of Navarra has identified a molecule as possibly effective for improving the treatment of chronic hepatitis and liver cancer. This research, coordinated by the doctors Jess Prieto, Esther Larrea, Pablo Sarobe, Iranzu Gonzlez and Rafael Aldabe, has been published in the Journal of Virology; a journal of the American Society of Microbiology.
Genetic analysis predicts whether liver cancer likely to recur
October 16, 2008 by admin · Leave a Comment
New technology makes it possible to study tissue samples locked away for decades
Researchers are poised to unlock the genetic secrets stored in hundreds of thousands of cancer biopsy samples locked in long-term storage and previously thought to be useless for modern genetic research. With the aid of a new technique developed by Howard Hughes Medical Institute researchers, scientists can now reconstruct thousands of genes that are “shredded” into tiny pieces when tissue samples are treated with a chemical fixative and stored in wax a protocol that is commonly used to preserve the samples.
Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported today at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines. The team is currently designing a trial to test the combination in patients.
Combined stenting and photodynamic therapy improves survival in late stage liver cancer patients
March 11, 2008 by admin · Leave a Comment
A combined therapeutic approach of stenting and photodynamic therapy may improve survival rates for patients suffering from advanced liver bile duct cancer, according to a study published this month in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.
Discovery of good — and bad — liver stem cells raises possibility of new treatment
February 8, 2008 by admin · Leave a Comment
Many scientists believe up to 40 percent of liver cancer is caused by stem cells gone wild master cells in the organ that have lost all growth control. But, despite years spent looking, no one has ever found these liver cancer stem cells or even normal stem cells in the organ. Until now.
